Terms: = Prostate cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5 AND Diagnosis
19 results:
1. Gender-specific counselling of patients with upper tract urothelial carcinoma and Lynch syndrome.
Cerrato C; Pandolfo SD; Autorino R; Panunzio A; Tafuri A; Porcaro AB; Veccia A; De Marco V; Cerruto MA; Antonelli A; Derweesh IH; Maresma MCM
World J Urol; 2023 Jul; 41(7):1741-1749. PubMed ID: 36964236
[TBL] [Abstract] [Full Text] [Related]
2. A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months.
Shimizu K; Sano T; Mizuno K; Sunada T; Makita N; Hagimoto H; Goto T; Sawada A; Fujimoto M; Ichioka K; Ogawa O; Kobayashi T; Akamatsu S
Cold Spring Harb Mol Case Stud; 2022 Jun; 8(4):. PubMed ID: 35487690
[TBL] [Abstract] [Full Text] [Related]
3. Early age of onset and broad cancer spectrum persist in msh6- and PMS2-associated Lynch syndrome.
Liu YL; Cadoo KA; Maio A; Patel Z; Kemel Y; Salo-Mullen E; Catchings A; Ranganathan M; Kane S; Soslow R; Ceyhan-Birsoy O; Mandelker D; Carlo MI; Walsh MF; Shia J; Markowitz AJ; Offit K; Stadler ZK; Latham A
Genet Med; 2022 Jun; 24(6):1187-1195. PubMed ID: 35346574
[TBL] [Abstract] [Full Text] [Related]
4. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
Bancroft EK; Page EC; Brook MN; Thomas S; Taylor N; Pope J; McHugh J; Jones AB; Karlsson Q; Merson S; Ong KR; Hoffman J; Huber C; Maehle L; Grindedal EM; Stormorken A; Evans DG; Rothwell J; Lalloo F; Brady AF; Bartlett M; Snape K; Hanson H; James P; McKinley J; Mascarenhas L; Syngal S; Ukaegbu C; Side L; Thomas T; Barwell J; Teixeira MR; Izatt L; Suri M; Macrae FA; Poplawski N; Chen-Shtoyerman R; Ahmed M; Musgrave H; Nicolai N; Greenhalgh L; Brewer C; Pachter N; Spigelman AD; Azzabi A; Helfand BT; Halliday D; Buys S; Ramon Y Cajal T; Donaldson A; Cooney KA; Harris M; McGrath J; Davidson R; Taylor A; Cooke P; Myhill K; Hogben M; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Dias A; Dudderidge T; Eccles DM; Green K; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lilja H; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra AV; Moynihan C; Ni Raghallaigh H; Rennert G; Collier R; ; Offman J; Kote-Jarai Z; Eeles RA
Lancet Oncol; 2021 Nov; 22(11):1618-1631. PubMed ID: 34678156
[TBL] [Abstract] [Full Text] [Related]
5. Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
Wei J; Yang W; Shi Z; Lu L; Wang Q; Resurreccion WK; Engelmann V; Zheng SL; Hulick PJ; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J
Prostate; 2021 Sep; 81(13):1002-1008. PubMed ID: 34254341
[TBL] [Abstract] [Full Text] [Related]
6. Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.
Laish I; Friedman E; Levi-Reznick G; Kedar I; Katz L; Levi Z; Halpern N; Parnasa S; Abu-Shatya A; Half E; Goldberg Y
Breast Cancer Res Treat; 2021 Aug; 188(3):685-694. PubMed ID: 34086170
[TBL] [Abstract] [Full Text] [Related]
7. Prevalence and clinicopathological/molecular characteristics of mismatch repair protein-deficient tumours among surgically treated patients with prostate cancer in a Japanese hospital-based population.
Kagawa M; Kawakami S; Yamamoto A; Suzuki O; Eguchi H; Okazaki Y; Akagi K; Tamaru JI; Arai T; Yamaguchi T; Ishida H
Jpn J Clin Oncol; 2021 Apr; 51(4):639-645. PubMed ID: 33244609
[TBL] [Abstract] [Full Text] [Related]
8. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer.
Chan E; Garg K; Stohr BA
Mod Pathol; 2020 Sep; 33(9):1802-1810. PubMed ID: 32313185
[TBL] [Abstract] [Full Text] [Related]
9. Clinical Features and Therapeutic Outcomes in Men with Advanced prostate cancer and DNA Mismatch Repair Gene Mutations.
Antonarakis ES; Shaukat F; Isaacsson Velho P; Kaur H; Shenderov E; Pardoll DM; Lotan TL
Eur Urol; 2019 Mar; 75(3):378-382. PubMed ID: 30337059
[TBL] [Abstract] [Full Text] [Related]
10. Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous prostate cancer with Intact MMR: diagnosis and Analysis of the Family Pedigree.
Liu W; Zhang D; Tan SA; Liu X; Lai J
Anticancer Res; 2018 Aug; 38(8):4847-4852. PubMed ID: 30061258
[TBL] [Abstract] [Full Text] [Related]
11. Tumor development in Japanese patients with Lynch syndrome.
Saita C; Yamaguchi T; Horiguchi SI; Yamada R; Takao M; Iijima T; Wakaume R; Aruga T; Tabata T; Koizumi K
PLoS One; 2018; 13(4):e0195572. PubMed ID: 29672549
[TBL] [Abstract] [Full Text] [Related]
12. Sebaceous tumours: more than skin deep.
Jockenhöfer F; Schimming TT; Schaller J; Moege J; Livingstone E; Salva KA; Zimmer L; Schadendorf D; Rösch A
Gut; 2018 Nov; 67(11):1957. PubMed ID: 29247065
[TBL] [Abstract] [Full Text] [Related]
13. prostate cancer Screening in a New Era of Genetics.
Cheng HH; Pritchard CC; Montgomery B; Lin DW; Nelson PS
Clin Genitourin Cancer; 2017 Dec; 15(6):625-628. PubMed ID: 28697982
[TBL] [Abstract] [Full Text] [Related]
14. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.
Schweizer MT; Cheng HH; Tretiakova MS; Vakar-Lopez F; Klemfuss N; Konnick EQ; Mostaghel EA; Nelson PS; Yu EY; Montgomery B; True LD; Pritchard CC
Oncotarget; 2016 Dec; 7(50):82504-82510. PubMed ID: 27756888
[TBL] [Abstract] [Full Text] [Related]
15. A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer.
Kerr L; Rewhorn MJ; Longmuir M; Fraser S; Walsh S; Andrew N; Leung HY
BMC Cancer; 2016 Jul; 16():529. PubMed ID: 27456091
[TBL] [Abstract] [Full Text] [Related]
16. High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry.
Rosty C; Walsh MD; Lindor NM; Thibodeau SN; Mundt E; Gallinger S; Aronson M; Pollett A; Baron JA; Pearson S; Clendenning M; Walters RJ; Nagler BN; Crawford WJ; Young JP; Winship I; Win AK; Hopper JL; Jenkins MA; Buchanan DD
Fam Cancer; 2014 Dec; 13(4):573-82. PubMed ID: 25117503
[TBL] [Abstract] [Full Text] [Related]
17. Commentary on "Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome." Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Clendenning M, Rosty C, Arnold J, Levine AJ, Haile RW, Gallinger S, Le Marchand L, Newcomb PA, Hopper JL, Jenkins MA, Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Population Health, The University of Melbourne, Victoria, Australia: J Natl cancer Inst 2012;104(18):1363-72 [Epub 2012 Aug 28].
See WA
Urol Oncol; 2013 Jul; 31(5):716. PubMed ID: 23796201
[TBL] [Abstract] [Full Text] [Related]
18. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.
Win AK; Lindor NM; Young JP; Macrae FA; Young GP; Williamson E; Parry S; Goldblatt J; Lipton L; Winship I; Leggett B; Tucker KM; Giles GG; Buchanan DD; Clendenning M; Rosty C; Arnold J; Levine AJ; Haile RW; Gallinger S; Le Marchand L; Newcomb PA; Hopper JL; Jenkins MA
J Natl Cancer Inst; 2012 Sep; 104(18):1363-72. PubMed ID: 22933731
[TBL] [Abstract] [Full Text] [Related]
19. cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry.
Pande M; Wei C; Chen J; Amos CI; Lynch PM; Lu KH; Lucio LA; Boyd-Rogers SG; Bannon SA; Mork ME; Frazier ML
Fam Cancer; 2012 Sep; 11(3):441-7. PubMed ID: 22714864
[TBL] [Abstract] [Full Text] [Related]
